RA0220

antibody from Oursmab

Targeting: ERBB2 CD340, HER-2, HER2, NEU, NGL

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0220

Provider

Oursmab

Product name

Anvatabart (Biosimilar Reference Antibody) (ERBB2)

Antibody type

Monoclonal

Description

Anvatabart is a clinical-stage, site-specific antibody-drug conjugate (ADC) designed for the treatment of HER2 (ERBB2)-positive solid tumors. It is comprised of a fully human anti-HER2 IgG1¦Ê monoclonal antibody, which is site-specifically conjugated to a proprietary, highly potent microtubule inhibitor payload, AS269. This precise conjugation through non-natural amino acid technology aims to produce a homogeneous ADC with a controlled drug-to-antibody ratio (DAR ¡Ö 1.8). It is designed to deliver cytotoxic payload directly to HER2-expressing tumor cells with high stability in circulation. It is currently in global Phase II/III clinical trials for metastatic breast cancer and other HER2-positive cancers, representing a next-generation ADC candidate.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.